• / Free eNewsletters & Magazine
  • / My Account
Home>No Surprises in Medtronic's Fiscal Third Quarter

No Surprises in Medtronic's Fiscal Third Quarter

Morningstar Articles

Wed, 19 Feb 2014

The firm is on track to meet our full-year estimates, and our $60 per share fair value estimate and wide moat rating are intact.

Related Videos

  1. Google Still Worth Owning Despite Shareholder Setbacks

    Although the Motorola sale and proposed stock split aren't the best for shareholders, the Internet giant has a very wide moat and excellent management, says StockInvestor editor Matt Coffina.

  2. Morningstar Minute: 3 Pillars to Express Scripts' Wide Moat

    Pharmacy benefits manager Express Scripts is attractively priced given its ability to fend off competitors for years to come.

  3. Super-Wide Moat in the Making at Medtronic

    The device maker's planned acquisition of Covidien will make it a force to be reckoned with.

©2017 Morningstar Advisor. All right reserved.